menu

Key Takeaways from the IPF Experts at the Pulmonary Fibrosis Foundation's PFF Summit

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Key Takeaways from the IPF Experts at the Pulmonary Fibrosis Foundation's PFF Summit

Hear from experts in the field of pulmonary medicine from the recent Pulmonary Fibrosis Foundation's PFF Summit.

Available credits: 1.00

Time to complete: 60 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial pneumonias, accounting for as many as 40,000 deaths per year in the United States. There is no cure for IPF, and although two recently approved drugs have been shown to delay progression, prognosis remains poor, with an estimated median survival of about 4 years. Recent research into the genetics and the pathophysiology of the disease has identified a number of potential therapeutic targets that offer hope for improving the management – and potentially for preventing – the disease. The availability of a nationwide Clinical Care Network focused on IPF and the launch of a patient registry are other developments that have improved the outlook for patients and their caregivers. Clinicians would benefit from hearing summaries of scientific presentations by leading experts in IPF from the recent Pulmonary Fibrosis Foundation's PFF Summit.

     

  • Providers

    Jointly provided by Global Academy for Medical Education and Postgraduate Institute for Medicine, in collaboration with Pulmonary Fibrosis Foundation.

          

     

  • Commercial Support

    Supported by educational grants from Genentech and Boehringer Ingelheim.

  • Faculty

    Gregory P. Cosgrove, MD, FCCP
    National Jewish Health
    University of Colorado Denver
    Denver, Colorado
    Pulmonary Fibrosis Foundation

    Christina Garcia, MD, PhD
    Kern and Marnie Wildenthal President’s Research Council
    Endowed Professor, Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Department of Internal Medicine,
    University of Texas Southwestern Medical Center
    Dallas, Texas

    Sonye K. Danoff, MD, PhD
    Assistant Professor, Division of Pulmonary and Critical Care Medicine
    Co-Director of the Hopkins Interstitial Lung Disease Clinic
    Johns Hopkins University
    Baltimore, Maryland

    Victor J. Thannickal, MD
    Professor, Ben Vaughan Branscomb Chair of Medicine in Respiratory Disease
    Director, Division of Pulmonary, Allergy, and Critical Care
    Vice Chair for Research, Department of Medicine
    University of Alabama
    Birmingham, Alabama

  • Target Audience

    This activity is intended for pulmonologists, family practitioners, internists, nurse practitioners, physician assistants, and other clinicians who treat patients with idiopathic pulmonary fibrosis (IPF).

  • Method of Participation

    Participants should read the CME/CE information, review the activity in its entirety, and complete the online post-test and evaluation. Upon completing this activity as designed and achieving a passing score on the post-test, you will be emailed a link to view and download your certificate. 

    Inquiries may be directed to Global Academy for Medical Education at info@globalacademycme.com or (973) 290-8225.

  • Learning Objectives

    • Describe recent advances in the genetics of pulmonary fibrosis pathogenesis and how they can be applied to improved patient care.
    • Review clinical trial data supporting the efficacy and safety of pirfenidone and nintedanib.
    • Explain the potential role of senolytic drugs in the management of IPF.
    • Discuss emerging resources available for managing IPF, including the Clinical Care Network and the patient registry.
  • Accreditation Statements

    Physicians: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Global Academy for

    Medical Education. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

    Postgraduate Institute of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nurses: The Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

    This educational activity for 1.0 contact hours is provided by Postgraduate Institute for Medicine.

     

  • Disclosure Declarations

    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

    Gregory P. Cosgrove, MD: Consultant: Boehringer Ingelheim. Genentech, Global Blood Therapeutics, Global Academy for Medical Education. Grant/Research Support: Boehringer Ingelheim, Bristol Myers Squibb, Genentech, and Global Blood Therapeutics.

    Sonye Danoff, MD: Consultant: Boehringer Ingelheim. Global Blood Therapeutics. Grant/Research Support: Boehringer Ingelheim, Genentech Hoffman LaRoche.

    Christina Garcia, MD: Consultant: Pliart Therapeutic

    Victor J. Thannickal, MD: Has no conflicts of interest to report.  

    Off-Label/Investigational Use Disclosure

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Contact Information for Technical Questions

    Please technical questions or concerns to Global Academy for Medical Education at 973-290-8225 or email info@globalacademycme.com.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.